Systemic mycoses in immunodepressed patients (AIDS)

Clinics in Dermatology

Volumn 30, Issue 6, 2012, Pages 616-627

  Ramos e Silva, Marcia ^a   Lima, Cíntia Maria Oliveira ^a   Schechtman, Regina Casz ^a   Trope, Beatriz Moritz ^a   Carneiro, Sueli ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIVIRUS AGENT; CASPOFUNGIN; COTRIMOXAZOLE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; RITONAVIR; TENOFOVIR; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASPERGILLOSIS; BLASTOMYCOSIS; CENTRAL NERVOUS SYSTEM INFECTION; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; CUTANEOUS CRYPTOCOCCOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMOSIS; HUMAN; INFECTION RISK; KIDNEY FUNCTION; LOADING DRUG DOSE; LUNG INFECTION; LUNG INFILTRATE; NONHUMAN; NOTE; PENICILLIOSIS; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOUTH AMERICAN BLASTOMYCOSIS; SPOROTRICHOSIS; SYSTEMIC MYCOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; DERMATOMYCOSES; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES;

EID: 84867587364     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.01.008     Document Type: Note

References (90)

1. Raju P.V., Rao G.R., Ramani T.V., Vandana S. Skin disease: clinical indicator of immune status in human immunodeficiency virus (HIV) infection. Int J Dermatol 2005, 44:646-649.
2. Rad F., Ghaderi E., Moradi G., Mafakheri L. The relationship between skin manifestations and CD4 counts among HIV positive patients. Pak J Med Sci 2008, 24:114-117.
3. Negroni R. Micosis sistémicas tropicales asociadas al sida. Enf Emerg 2003, 5:27-40.
4. Trope B.M., Lenzi M.E. Infecção pelo HIV. Fundamentos de dermatologia 2009, 1003-1027. Rio de Janeiro, Atheneu. M. Ramos-e-Silva, M.C.R. Castro (Eds.).
5. Venkatesan P., Perfect J.R., Myers S.A. Evaluation and management of fungal infections in immunocompromised patients. Dermatol Ther 2005, 18:44-57.
6. Fernandes O.F.L., Costa T.R., Costa M.R., et al. Cryptococcus neoformans isolados de pacientes com AIDS. [Cryptococcus neoformans isolated from patients with AIDS]. Rev Soc Bras Med Trop 2000, 33:75-78.
7. Filiú W.F., Wanke B., Agüena S.M., Vilela V.O., Macedo R.C., Lazéra M. Cativeiro de aves como fonte de Cryptococus neoformans na cidade de Campo Grande, no Mato Grosso do Sul, Brasil. [Avian habitats as sources of Cryptococcus neoformans in the city of Campo Grande, Mato Grosso do Sul, Brazil]. Rev Soc Bras Med Trop 2002, 35:591-595.
8. Moreira Tde A., Ferreira M.S., Ribas R.M. Borges AS. Criptococose: estudo clínico-epidemiológico, laboratorial e das variedades do fungo em 96 pacientes. [Cryptococcosis: clinical epidemiological laboratorial study and fungi varieties in 96 patients]. Rev Soc Bras Med Trop 2006, 39:255-258.
9. Harrison T.S., Brouwer A.E. Systemic fungal infections. Medicine 2009, 37:660-664.
10. Kovarik C.L., Barnard J.J. Fatal disseminated cryptococcus as the initial presentation of HIV infection in the era of highly active antiretroviral therapy. J Forensic Sci 2009, 54:927-929.
11. Chen S., Sorrell T., Nimmo G., et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 2000, 31:499-508.
12. Samaranayake L.P., Leung W.K., Jin L. Oral mucosal fungal infections. Periodontology 2000 2009, 49:39-59.
13. Dromer F., Mathoulin-Pélissier S., Launay O., Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007, 4:e21. French Cryptococcosis Study Group.
14. Lortholary O., Poizat G., Zeller V., et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 2006, 20:2183-2191.
15. Garman M.E., Tyring S.K. The cutaneous manifestations of HIV infection. Dermatol Clin 2002, 20:193-208.
16. Perfect J.R., Dismukes W.E., Dromer F., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:291-322.
17. Jarvis J.N., Lawn S.D., Vogt M., Bangani N., Wood R., Harrison T.S. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009, 48:856-862.
18. Hernández S.L., López de Blanc S.A., Sambuelli R.H., et al. Oral histoplasmosis associated with HIV infection: a comparative study. J Oral Pathol Med 2004, 33:445-450.
19. Couppié P., Aznar C., Carme B., Nacher M. American histoplasmosis in developing countries with a special focus on patients with HIV: diagnosis, treatment, and prognosis. Curr Opin Infect Dis 2006, 19:443-449.
20. Bonifaz A., Chang P., Moreno K., et al. Disseminated cutaneous histoplasmosis in acquired immunodeficiency syndrome: report of 23 cases. Clin Exp Dermatol 2008, 34:481-486.
21. Rosenberg J.D., Scheinfeld N.S. Cutaneous histoplasmosis in patients with acquired immunodeficiency syndrome. Cutis 2003, 72:439-445.
22. Cunha V.S., Zampese M.S., Aquino V.R., Cestari T.F., Goldani L.Z. Mucocutaneous manifestations of disseminated histoplasmosis in patients with acquired immunodeficiency syndrome: particular aspects in a Latin-American population. Clin Exp Dermatol 2007, 32:250-255.
23. Scheinfeld N. Diffuse ulcerations due to disseminated histoplasmosis in a patient with HIV. J Drugs Dermatol 2003, 2:189-191.
24. Bianchi M., Robles A.M., Vitale R., Helou S., Arechavala A., Negroni R. The usefulness of blood culture in diagnosing HIV-related systemic mycoses: evaluation of a manual lysis centrifugation method. Med Mycol 2000, 38:77-80.
25. Luther J.M., Lakey D.L., Larson R.S., et al. Utility of bone marrow biopsy for rapid diagnosis of febrile illnesses in patients with human immunodeficiency virus infection. South Med J 2000, 93:692-697.
26. Akpek G., Lee S.M., Gagnon D.R., Cooley T.P., Wright D.G. Bone marrow aspiration, biopsy and culture in the evaluation of HIV-infected patients for invasive mycobacteria and histoplasma infections. Am J Hematol 2001, 67:100-106.
27. Negroni R. La histoplasmosis asociada al SIDA en los años del tratamiento antirretroviral (T.A.R.). El Muñiz Hoy 2000, 3:102-107.
28. Garringer T.O., Wheat L.J., Brizendine E.J. Comparison of an established antibody sandwich method with an inhibition method of Histoplasma capsulatum antigen detection. J Clin Microbiol 2000, 38:2909-2913.
29. Wheat L.J., Cloud G., Johnson P.C., et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal anfotericin B versus itraconazole. Antimicrob Agents Chemother 2001, 45:2354-2357.
30. Wheat L.J., Connolly P., Haddad N., Le Monte A., Brizendine E., Hafner R. Antigen clearance during treatment of disseminated histoplasmosis with itraconazole vs fluconazole in patients with AIDS. Antimicrob Agents Chemother 2002, 46:248-250.
31. Wheat J., Sarosi G., McKinsey D., et al. Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin Infect Dis 2000, 30:688-695.
32. Marques S.A., Robles A.M., Tortorano A.M., Tuculet M.A., Negroni R., Mendes R.P. Mycoses associated with AIDS in the Third World. Med Mycol 2000, 38:269-279.
33. Johnson R.A. HIV disease: mucocutaneous fungal infections in HIV disease. Clin Dermatol 2000, 18:411-422.
34. Ampel N.M. Coccidioidomycosis in persons infected with HIV Type 1. Clin Infect Dis 2005, 41:1174-1178.
35. Mateos García E., Gaytán Martínez J.E., Casanova L.J., et al. Coccidioidomicosis diseminada: manifestación inicial de SIDA en residente de área no endémica. Rev Med IMSS 2000, 38:433-436.
36. Batura-Gabryel H., Brajer B. Coccidioidomycosis in a 38-year-old man: a case report. Pol Arch Med Wewn 2008, 118:387-389.
37. Dupont B., Crewe Brown H.H., Westermann K., et al. Mycoses in AIDS. Med Mycol 2000, 38:259-267.
38. Galgiani J.N., Catanzaro A., Cloud G.A., et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized double-blind trial. Ann Intern Med 2000, 133:676-686.
39. Cortez K.J., Walsh T.J., Bennett J.E. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003, 36:1619-1622.
40. Boucher H.W., Groll A.H., Chiou C.C., Walsh T.J. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004, 64:1997-2020.
41. Koks C.H., Crommentuyn K.M., Hoetelmans R.M., et al. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1 infected individuals. Br J Clin Pharmacol 2001, 51:631-635.
42. Purkins L., Wood N., Kleinermans D., Love E.R. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol 2003, 56:62-68.
43. Crommentuyn K.M., Mulder J.W., Sparidans R.W., Huitema A.D., Schellens J.H., Beijnen J.H. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Clin Infect Dis 2004, 38:e73-e75.
44. Mauss S., Berger F., Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005, 19:93-95.
45. Ruhnke M. Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment. Drugs 2004, 64:1163-1180.
46. Mussini C., Pezzotti P., Mire J., et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004, 38:565-571.
47. Goldman M., Zackin R., Fichtenbaurn C., et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis 2004, 38:1485-1489.
48. Proia A.L. Treatment of blastomycosis. Curr Fungal Infect Rep 2010, 4:23-29.
49. Fisher K.R., Baselski V., Beard G., Chesney T.M., Threlkeld S.C., Skinner R.B. Pustular blastomycosis. J Am Acad Dermatol 2009, 61:355-358.
50. Dworkin M.S., Duckro A.N., Proia L., Semel J.D., Huhn G. The epidemiology of blastomycosis in Illinois and factors associated with death. Clin Infect Dis 2005, 41:e107-e111.
51. Dwight P.J., Naus M., Sarsfield P., Limerick B. An outbreak of human blastomycosis: the epidemiology of blastomycosis in the Kenora catchment region of Ontario, Canada. Can Commun Dis Rep 2000, 26:82-91.
52. Chapman S.W., Dismukes W.E., Proia L.A., et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:1801-1812.
53. Bradsher R.W. Pulmonary blastomycosis. Semin Respir Crit Care Med 2008, 29:174-181.
54. Crampton T.L., Light R.B., Berg G.M., et al. Epidemiology and clinical spectrum of blastomycosis diagnosed at Manitoba hospitals. Clin Infect Dis 2002, 34:1310-1316.
55. Vyas K.S., Bariola J.R., Bradsher R.W. Advances in the serodiagnosis of blastomycosis. Curr Fung Infect Rep 2008, 2:227-231.
56. Bradsher R.W., Chapman S.W., Pappas P.G. Blastomycosis. Infect Dis Clin North Am 2003, 17:21-40.
57. Morejón K.M., Machado A.A., Martinez R. Paracoccidioidomycosis in patients infected with and not infected with human immunodeficiency virus: a case-control study. Am J Trop Med Hyg 2009, 80:359-366.
58. Formari M.C., Bava A.J., Guereno M.T., et al. High serum interleukin-10 and tumor necrosis factor alpha levels in chronic paracoccidioidomycosis. Clin Diagn Lab Immunol 2001, 8:1036-1038.
59. Benard G., Duarte A.J. Paracoccidioidomycosis: a model for evaluation of the effects of human immunodeficiency virus infection on the natural history of endemic tropical diseases. Clin Infect Dis 2000, 31:1032-1039.
60. Paniago A.M., Freitas A.C., Aguiar E.S., et al. Paracoccidioidomycosis in patients with human immunodeficiency virus: review of 12 cases observed in an endemic region in Brazil. J Infect 2005, 51:248-252.
61. Castro G., Martinez R. Images in clinical medicine. Disseminated paracoccidioidomycosis and coinfection with HIV. N Engl J Med 2006, 355:2677.
62. Silva-Vergara M.L., Teixeira A.C., Curi V.G., et al. Paracoccidioidomycosis associated with human immunodeficiency virus infection. Report of 10 cases. Med Mycol 2003, 41:259-263.
63. Shikanai-Yasuda M.A., Telles Filho Fde Q., Mendes R.P., Colombo A.L., Moretti M.L. Consenso em paracoccidioidomicose. [Guidelines in paracoccidioidomycosis]. Rev Soc Bras Med Trop 2006, 39:297-310.
64. Carvalho M.T., de Castro A.P., Baby C., Werner B., Filus Neto J., Queiroz-Telles F. Disseminated cutaneous sporotrichosis in a patient with AIDS: report of a case. Rev Soc Bras Med Trop 2002, 35:655-659.
65. Hardman S., Stephenson I., Jenkins D.R., Wiselka M.J., Johnson E.M. Disseminated Sporothix schenckii in a patient with AIDS. J Infect 2005, 51:e73-e77.
66. de Lima Barros M.B., Schubach T.M., Galhardo M.C., et al. Sporotrichosis: an emergent zoonosis in Rio de Janeiro. Mem Inst Oswaldo Cruz 2001, 96:777-779.
67. Nobre M.O., Castro A.P., Caetano D., Souza L.L., Meireles M.C.A., Ferreiro L. Recurrence of sporotrichosis in cats with zoonotic envolvement. Rev Iberoam Micol 2001, 18:137-140.
68. Schubach T.M.P., Valle A.C.F., Gutiérrez-Galhardo M.C., et al. Isolation of Sporothrix schenckii from the nails of domestic cats. (Felis catus). Med Mycol 2001, 39:147-149.
69. Schubach T.M.P., Schubach A de O., Reis R.S.C., et al. Sporothrix schenkii isolated from domestic cats with and without sporotrichosis in Rio de Janeiro, Brazil. Mycopathologia 2001, 153:83-86.
70. Edwards C., Reuther W.L., Greer D.L. Disseminated osteoarticular sporotrichosis: treatment in a patient with acquired immunodeficiency syndrome. South Med J 2000, 93:803-806.
71. Rocha M.M., Dassin T., Lira R., Lima E.L., Severo L.C., Londero A.T. Sporotrichosis in patient with AIDS. Rev Iberoam Micol 2001, 18:133-136.
72. Kauffman C.A., Hajjeh R., Chapman S.W. Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America. Clin Infect Dis 2000, 30:684-687.
73. Hien T.V., Loc P.P., Hoa N.T., et al. First cases of disseminated Penicillosis marneffei infection among patients with acquired immunodeficiency syndrome in Vietnam. Clin Infect Dis 2001, 32:e78-e80.
74. Sirisanthana T. Penicillium marneffei infection in patients with AIDS. Emerg Infect Dis 2001, 7:561.
75. Karp C.L., Auwaerte P.G. Coinfection with HIV and tropical infectious diseases. II. Helminthic, fungal, bacterial, and viral pathogens. Clin Infect Dis 2007, 45:1214-1220.
76. Bateman A.C., Jones G.R., O'Connell S., Clark F.J., Plummeridge M. Massive hepatosplenomegaly caused by Penicillium marneffei associated with human immunodeficiency virus infection in a Thai patient. J Clin Pathol 2002, 55:43-44.
77. Kudeken N., Kawakami K., Saito A. Mechanisms of the in vitro fungicidal effects of human neutrophils against Penicillium marneffei induced by granulocyte-macrophage colony-stimulating factor (GM-CSF). Clin Exp Immunol 2000, 119:472-478.
78. Hung C.C., Chen M.Y., Hsieh S.M., Sheng W.H., Hsiao C.F., Chang S.C. Discontinuation of secondary prophylaxis for penicillosis marnefei in AIDS patients responding to highly active antiretroviral therapy. AIDS 2002, 16:672-673.
79. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guideline of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.
80. Roilides E., Farmaki E. Human immunodeficiency virus infection and cutaneous aspergillosis. Arch Dermatol 2000, 136:412-414.
81. Mylonakis E., Paliou M., Sax P.E., Skolnik P.R., Baron M.J., Rich J.D. Central nervous system aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and review. Medicine (Baltimore) 2000, 79:269-280.
82. van Hal S.J., Clezy K. Emergence of invasive cerebral aspergillosis in an HIV-positive patient on voriconazole therapy. HIV Med 2005, 6:45-46.
83. Lin S.J., Schranz J., Teutsch S.M. Aspergillosis case-fatality rate. Systematic review of the literature. Clin Infect Dis 2001, 32:358-366.
84. Nadkarni T., Goel A. Aspergilloma of the brain: an overview. J Postgrad Med 2005, 51:S37-S41.
85. Metta H., Corti M., Redini L., et al. Renal abscess due to Aspergillus fumigatus as the only sign of disseminated aspergillosis in a patient with AIDS. Rev Iberoam Micol 2010, 27:136-139.
86. Muñoz P., Guinea J., Bouza E. Update on invasive aspergillosis: clinical and diagnostic aspects. Clin Microbiol Infect 2006, 12:24-39.
87. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
88. Deresinski S.C., Stevens D.A. Caspofungin. Clin Infect Dis 2003, 36:1445-1457.
89. Ellis M., Watson R., McNabb A., Lukic M.L., Nork M. Massive intracerebral aspergillosis responding to combination high-dose liposomal amphotericin B and cytokine therapy without surgery. J Med Microbiol 2002, 51:70-75.
90. Roilides E., Lamaignere C.G., Farmaki E. Cytokines in immunodeficient patients with invasive fungal infections: an emerging therapy. Int J Infect Dis 2002, 6:154-163.